Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Share-based Compensation (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Share-based Compensation for 12 consecutive years, with $4.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Share-based Compensation rose 106.67% year-over-year to $4.1 million, compared with a TTM value of $6.7 million through Sep 2025, down 19.54%, and an annual FY2024 reading of $7.7 million, down 10.4% over the prior year.
  • Share-based Compensation was $4.1 million for Q3 2025 at CytomX Therapeutics, up from $200000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $4.1 million in Q3 2025 and bottomed at -$10.5 million in Q4 2022.
  • Average Share-based Compensation over 5 years is $927052.6, with a median of $2.0 million recorded in 2024.
  • The sharpest move saw Share-based Compensation surged 137.1% in 2023, then tumbled 89.37% in 2025.
  • Year by year, Share-based Compensation stood at -$9.6 million in 2021, then fell by 9.11% to -$10.5 million in 2022, then soared by 124.3% to $2.6 million in 2023, then decreased by 26.18% to $1.9 million in 2024, then soared by 118.84% to $4.1 million in 2025.
  • Business Quant data shows Share-based Compensation for CTMX at $4.1 million in Q3 2025, $200000.0 in Q2 2025, and $500000.0 in Q1 2025.